Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

;

The data from this abstract demonstrated that RB006 (1mg/kg, IV) results in consistent and near complete inhibition of FIX in patients with ACS with stable anti-coagulation throughout catheterization (PCI).  These findings further validate the dosing of RB006 for Regado's ongoing and planned clinical trials.

The abstract is coauthored by Thomas J. Povsic, MD, Ph.D., Richard A. Becker, MD, and John H. Alexander, MD, MHS, all from Duke University Medical Center; Christopher P. Rusconi, Ph.D., Steven L. Zelenkofske, D.O., both from Regado Biosciences; and William Wargin, Ph.D., President of PK-PM Associates, LLC; Mauricio G. Cohen, MD, University of Miami Miller School of Medicine; Roxana Mehran, MD, Mount Sinai School of Medicine; Christoph Bode, MD, University of Freiburg, Germany; Joshua Krasnow, MD, Heart Center Research, LLC; and Merrill Krolick, D.O., Heart and Vascular Institute of Florida.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1,
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Human Insulin Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore more ...
(Date:7/28/2015)... LINCOLNSHIRE, Ill. , July 28, 2015 ... acumen on par with their levels of clinical excellence. ... (AACC) Annual Meeting & Clinical Lab Expo, Sysmex is ... deliver a comprehensive and intuitive ecosystem that will help ... four key areas, Sysmex aims to add even more ...
(Date:7/28/2015)... July 28, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq: ... report its second quarter 2015 financial results after market ... management will follow the announcement with a live ... (1:30pm Pacific Time) to discuss the financial results. ... call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5Sysmex Moves Beyond a Better Box 2Sysmex Moves Beyond a Better Box 3Sysmex Moves Beyond a Better Box 4Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results 2
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim ... smooth state, and reduces the appearance of fine lines and wrinkles. , According to ... to instantly add volume to your cheek area to correct age-related volume loss in ...
(Date:7/28/2015)... ... ... Bipolar disorder is often associated with mood swings ranging from depressive lows ... World Health Organization (WHO) has reported that bipolar disorder affects about 60 million people ... United States has the highest lifetime rate of bipolar disorder at 4.4% affecting 14 ...
(Date:7/28/2015)... ... 28, 2015 , ... A new Taiwanese study suggests that ... in the general population. Surviving Mesothelioma has just posted an article detailing the ... Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the health records ...
(Date:7/28/2015)... ... ... A new study published by HealthDay News on June 24, 2015, entitled ... possible new treatment option for people living with fibromyalgia – hyperbaric oxygen therapy treatments ... per week, patients experienced a significant decrease in pain, fatigue, and other symptoms of ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... There has ... most people think of highways, bridges and railroads, often overlooked is the over ... our homes and buildings and into sewage treatment facilities. According to the American ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3
... premiere issue of an aging-focused newsletter deals with two ... care reform from the perspective of older minority ... The Gerontological Society of America (GSA), the country,s largest ... for this issue was provided by sanofi-aventis. Based ...
... antibodies that could block HIV, study finds , FRIDAY, ... of a major hurdle in efforts to develop an AIDs ... the immune system can produce B cells with the potential ... AIDS. But the immune system mistakenly perceives these cells as ...
... , , PASADENA, Calif., Dec. 18 ... Scouts of America (BSA), and with it comes an invitation to ... celebration is the BSA,s participation in the Tournament of Roses Parade, ... , "This is an incredibly exciting and important time for our ...
... , MINNEAPOLIS, Dec. 18 ... North Carolina and Tennessee are now offering H1N1 vaccinations ... necessary. The H1N1 vaccinations can be obtained at MinuteClinic ... outside the District of Columbia; in North Carolina in ...
... exploring another rite of passage when they get to ... level of maturity, some students may find less joy ... Alberta psychologists has found that emotionally mature students may ... counterparts. In a study on emotional experiences ...
... researchers from the University of Vigo, Rutgers University in ... United Kingdom, has developed "laser spinning", a novel method ... able to manufacture bioglass nanofibres, the bioactive glass used ... spinning makes it possible to produce glass nanofibres of ...
Cached Medicine News:Health News:Boy Scouts of America Launch 100th Year With Scouting Experience of a Lifetime 2Health News:Boy Scouts of America Launch 100th Year With Scouting Experience of a Lifetime 3Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 2Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 3Health News:Sex in university may be better for mature audiences: study 2
Therapeutic Drug Calibrator Series...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Medicine Products: